President Donald Trump at a meeting of the Coronavirus Task Force and pharmaceutical executives, March 2, 2020 (Kevin Dietsch/Sipa via AP Images)
November 13, 2020 09:28 AM ESTUpdated November 15, 12:53 PM
People
In Focus

As the cur­tain clos­es on the Trump pres­i­den­cy, biotech wres­tles with its fu­ture in a di­vid­ed Amer­i­ca

Jason Mast

Editor

At 11 am af­ter the elec­tion, Sher­lock Bio­sciences CEO Rahul Dhan­da snuck in­to his of­fice and, in the cou­ple min­utes be­tween meet­ings, fired off an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times